Literature DB >> 16878159

Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs.

A Mallakin1, P Taneja, L A Matise, M C Willingham, K Inoue.   

Abstract

Dmp1 is a Myb-like transcription factor that transmits oncogenic Ras-Raf signaling to the Arf-p53 pathway and induces cell cycle arrest. Immunohistochemical staining was performed to identify the pattern of Dmp1 expression in normal murine tissues compared with the proliferation marker, Ki67. In thymus, the nuclei of mature T lymphocytes in the medulla were strongly positive for Dmp1, whereas Ki67 was detected only in the cortex. In intestine, Dmp1 was detected in the nuclei of superficial layers of the villi, whereas Ki67-positive cells were confined to the lower one-third of the crypt. Double staining for Dmp1 and Ki67 revealed that these two proteins were expressed in mutually exclusive fashion in nearly all the tissues examined. Subsets of E2Fs were specifically bound to the Dmp1 promoter upon mitogenic signaling and E2Fs 1-4 inhibited the Dmp1 promoter in a reporter assay. The Dmp1 promoter was repressed when the cells entered the S to G2/M phase of the cell cycle when both Dmp1 and Arf expressions were downregulated. The Dmp1 mRNA was not downregulated by serum in E2F-DB(+) cells, suggesting that the Dmp1 promoter repression is E2F-dependent. This explains why the Dmp1 and Ki67-positive cells are stained in mutually exclusive fashion in normal tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878159      PMCID: PMC2077854          DOI: 10.1038/sj.onc.1209750

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Distinct cellular factors regulate the c-myb promoter through its E2F element.

Authors:  M R Campanero; M Armstrong; E Flemington
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

Review 2.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

3.  Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts.

Authors:  D N Chadee; M J Hendzel; C P Tylipski; C D Allis; D P Bazett-Jones; J A Wright; J R Davie
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

Review 4.  B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments.

Authors:  A Sala; R Watson
Journal:  J Cell Physiol       Date:  1999-06       Impact factor: 6.384

5.  E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.

Authors:  Z Lu; R Z Luo; H Peng; M Huang; A Nishmoto; K K Hunt; K Helin; W S-L Liao; Y Yu
Journal:  Oncogene       Date:  2006-01-12       Impact factor: 9.867

6.  Parameters involved in the conversion of real-time PCR assays from the ABI prism 7700 to the Cepheid SmartCycler II.

Authors:  Heather A Bentley; Dorothy R Belloni; Gregory J Tsongalis
Journal:  Clin Biochem       Date:  2005-02       Impact factor: 3.281

7.  Tumor spectrum in ARF-deficient mice.

Authors:  T Kamijo; S Bodner; E van de Kamp; D H Randle; C J Sherr
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

8.  Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.

Authors:  David Bertwistle; Frederique Zindy; Charles J Sherr; Martine F Roussel
Journal:  Hybrid Hybridomics       Date:  2004-10

9.  Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor.

Authors:  Ramesh Sreeramaneni; Asif Chaudhry; Martin McMahon; Charles J Sherr; Kazushi Inoue
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

Review 10.  The myb gene family in cell growth, differentiation and apoptosis.

Authors:  I H Oh; E P Reddy
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

View more
  29 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

2.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

Review 3.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

Review 4.  Network calisthenics: control of E2F dynamics in cell cycle entry.

Authors:  Jeffrey V Wong; Peng Dong; Joseph R Nevins; Bernard Mathey-Prevot; Lingchong You
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

5.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

6.  Long Non-coding RNA LINC01420 Contributes to Pancreatic Cancer Progression Through Targeting KRAS Proto-oncogene.

Authors:  Hongjun Zhai; Xinwu Zhang; Xiaoli Sun; Di Zhang; Shuangyu Ma
Journal:  Dig Dis Sci       Date:  2019-09-27       Impact factor: 3.199

7.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

8.  Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.

Authors:  Mario P Tschan; Elena A Federzoni; Aladin Haimovici; Christian Britschgi; Bettina A Moser; Jing Jin; Venkateshwar A Reddy; Dennis A Sheeter; Kimberlee M Fischer; Peiqing Sun; Bruce E Torbett
Journal:  Biochim Biophys Acta       Date:  2015-07-15

Review 9.  Transcription factors that interact with p53 and Mdm2.

Authors:  Kazushi Inoue; Elizabeth A Fry; Donna P Frazier
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

10.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.